DNX 314
Alternative Names: DNX-314Latest Information Update: 28 Nov 2022
At a glance
- Originator DNX Biopharmaceuticals; XL-protein GmbH
- Class Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Biobetters; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Osteoarthritis; Type 2 diabetes mellitus
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Osteoarthritis in Germany
- 28 Nov 2022 No recent reports of development identified for preclinical development in Osteoarthritis in USA
- 28 Nov 2022 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Germany